These results suggest a promising beneficial effect of GLP-1R agonists on endometrial cancer risk and on progression, even in the absence of obesity, although much remains to be investigated, especially regarding the potential of combining GLP-1R agonists with standard therapies (76). Here, GLP1R is linked to obesity disorder.